Your browser is no longer supported. Please, upgrade your browser.
ITCI Intra-Cellular Therapies, Inc. monthly Stock Chart
Intra-Cellular Therapies, Inc.
Index- P/E- EPS (ttm)-3.22 Insider Own3.50% Shs Outstand80.16M Perf Week-4.63%
Market Cap1.96B Forward P/E- EPS next Y-2.85 Insider Trans-6.07% Shs Float72.09M Perf Month-3.12%
Income-206.90M PEG- EPS next Q-0.86 Inst Own86.30% Short Float8.01% Perf Quarter35.72%
Sales10.40M P/S188.70 EPS this Y5.60% Inst Trans27.58% Short Ratio2.94 Perf Half Y15.29%
Book/sh10.20 P/B2.34 EPS next Y14.20% ROA-42.60% Target Price- Perf Year144.13%
Cash/sh8.79 P/C2.72 EPS next 5Y- ROE-48.30% 52W Range9.44 - 43.56 Perf YTD-30.34%
Dividend- P/FCF- EPS past 5Y-20.10% ROI- 52W High-42.86% Beta1.48
Dividend %- Quick Ratio19.50 Sales past 5Y- Gross Margin92.80% 52W Low163.67% ATR1.39
Employees330 Current Ratio19.60 Sales Q/Q- Oper. Margin- RSI (14)47.66 Volatility4.86% 6.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-25.70% Profit Margin- Rel Volume0.54 Prev Close23.90
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume1.96M Price24.89
Recom1.50 SMA20-2.40% SMA50-3.02% SMA20013.58% Volume599,912 Change4.14%
Feb-20-20Initiated Evercore ISI Outperform
Jan-31-20Downgrade JP Morgan Overweight → Neutral $26
Dec-24-19Reiterated Canaccord Genuity Buy $29 → $65
Aug-12-19Initiated Jefferies Buy $16
Feb-26-18Initiated JP Morgan Overweight
Feb-08-18Initiated RBC Capital Mkts Outperform $33
Dec-15-17Initiated Canaccord Genuity Buy $31
Nov-08-17Upgrade SunTrust Hold → Buy
Sep-07-17Upgrade Piper Jaffray Neutral → Overweight
Aug-30-17Upgrade Ladenburg Thalmann Neutral → Buy
Aug-24-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Aug-23-17Upgrade Leerink Partners Mkt Perform → Outperform
May-02-17Downgrade Leerink Partners Outperform → Mkt Perform
May-02-17Downgrade Ladenburg Thalmann Buy → Neutral
May-01-17Downgrade Piper Jaffray Overweight → Neutral
Dec-16-16Initiated Cantor Fitzgerald Overweight
Sep-29-16Reiterated RBC Capital Mkts Outperform $74 → $49
Sep-29-16Downgrade SunTrust Buy → Neutral
Sep-29-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-02-16Initiated Piper Jaffray Overweight
Dec-01-20 05:32AM  
Nov-30-20 08:00AM  
Nov-12-20 06:09AM  
Nov-09-20 06:00PM  
Nov-07-20 07:04AM  
Nov-04-20 08:00AM  
Oct-26-20 08:18AM  
Oct-04-20 06:20AM  
Oct-02-20 07:00AM  
Oct-01-20 04:30PM  
Sep-22-20 11:08AM  
Sep-15-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 08:42AM  
Sep-10-20 08:30PM  
Sep-09-20 05:12PM  
Sep-03-20 08:12AM  
Aug-10-20 05:30PM  
Aug-04-20 11:00AM  
Jul-28-20 10:30AM  
Jul-07-20 08:52AM  
Jun-29-20 08:00AM  
Jun-23-20 09:08PM  
Jun-17-20 04:04PM  
Jun-11-20 09:00AM  
Jun-04-20 08:49AM  
May-26-20 11:05AM  
May-14-20 08:00AM  
May-13-20 04:15PM  
May-09-20 09:52AM  
May-08-20 05:00PM  
May-07-20 11:05AM  
Apr-29-20 08:00AM  
Apr-27-20 09:05AM  
Apr-16-20 04:45PM  
Apr-07-20 06:12PM  
Apr-06-20 11:40PM  
Apr-02-20 08:00AM  
Mar-27-20 10:11AM  
Mar-23-20 07:30AM  
Mar-02-20 07:30AM  
Feb-25-20 08:45AM  
Feb-24-20 08:00AM  
Feb-21-20 04:15PM  
Feb-20-20 05:00PM  
Feb-18-20 10:13AM  
Jan-27-20 12:31PM  
Jan-21-20 08:50AM  
Jan-10-20 09:04AM  
Jan-08-20 08:12AM  
Jan-07-20 09:47PM  
Jan-06-20 04:06PM  
Jan-02-20 08:00AM  
Dec-31-19 11:36AM  
Dec-24-19 09:04AM  
Dec-23-19 04:15PM  
Dec-22-19 12:08PM  
Dec-20-19 10:24AM  
Dec-14-19 09:12PM  
Dec-12-19 08:08AM  
Dec-11-19 08:40AM  
Dec-09-19 09:18AM  
Dec-04-19 08:00AM  
Nov-21-19 02:31PM  
Nov-19-19 09:14AM  
Nov-11-19 10:16AM  
Nov-09-19 02:27PM  
Nov-05-19 07:30AM  
Oct-30-19 09:29AM  
Oct-29-19 08:00AM  
Oct-28-19 12:24PM  
Sep-30-19 08:00AM  
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Halstead MichaelEVP and General CounselNov 17Option Exercise13.8675,0001,039,50079,425Nov 19 08:05 PM
Halstead MichaelEVP and General CounselNov 17Sale27.6279,4252,193,4460Nov 19 08:05 PM
Hineline Lawrence J.SVP of Finance CFONov 11Option Exercise3.0520,00061,00028,034Nov 13 05:51 PM
Hineline Lawrence J.SVP of Finance CFONov 11Sale25.4128,034712,3440Nov 13 05:51 PM
Mates SharonChairman, President & CEONov 10Sale26.3450,0001,317,1011,113,392Nov 12 05:51 PM
Mates SharonChairman, President & CEONov 04Sale25.0050,0001,250,0001,163,392Nov 06 06:00 PM
Neumann MarkEVP, Chief Commercial OfficerOct 16Sale26.806,792182,02628,120Oct 16 04:04 PM
Alafi Christopher DDirectorSep 14Buy29.6049,5001,465,2004,743,770Sep 14 05:03 PM
Alafi Christopher DDirectorSep 11Buy28.0821,000589,6804,694,270Sep 11 04:15 PM
Hineline Lawrence J.SVP of Finance CFOSep 09Option Exercise12.7326,983343,49450,017Sep 11 07:08 PM
Hineline Lawrence J.SVP of Finance CFOSep 09Sale31.1441,9831,307,3518,034Sep 11 07:08 PM
MARCUS JOEL SDirectorMay 14Sale20.049,602192,42439,140May 15 05:37 PM
MARCUS JOEL SDirectorMay 13Sale20.637,297150,53714,374May 13 07:48 PM
LERNER RICHARD ADirectorMay 11Option Exercise2.7425,00068,50097,313May 13 05:20 PM
LERNER RICHARD ADirectorMay 11Sale20.503,50071,75093,813May 13 05:20 PM
MARCUS JOEL SDirectorMay 11Sale19.9550,000997,50048,742May 13 07:48 PM
Satlin AndrewEVP and Chief Medical OfficerJan 09Sale26.1611,573302,75011,338Jan 10 09:14 PM
Mates SharonChairman, President & CEOJan 09Sale26.1641,8951,095,9731,204,707Jan 10 09:09 PM
Halstead MichaelEVP and General CounselJan 09Sale26.1619,638513,730191Jan 10 09:06 PM
Hineline Lawrence J.SVP of Finance CFOJan 09Sale26.1619,638513,73018,800Jan 10 09:03 PM
Mates SharonChairman, President & CEOJan 08Option Exercise2.7460,000164,4001,246,602Jan 08 09:11 PM
Mates SharonChairman, President & CEOJan 06Sale30.2845,5981,380,8801,144,707Jan 08 09:11 PM
Halstead MichaelEVP and General CounselJan 06Sale30.3421,458651,007191Jan 08 09:02 PM
Hineline Lawrence J.SVP of Finance CFOJan 06Sale30.2921,458650,00318,800Jan 08 09:00 PM
Halstead MichaelEVP and General CounselJan 02Sale32.437,807253,214191Jan 03 09:17 PM
Hineline Lawrence J.SVP of Finance CFOJan 02Sale32.437,807253,16519,800Jan 03 09:16 PM
Mates SharonChairman, President & CEOJan 02Sale32.4517,478567,2301,144,707Jan 03 09:14 PM
Mates SharonChairman, President & CEODec 31Option Exercise2.746,00016,4401,162,185Jan 03 09:14 PM
Hineline Lawrence J.SVP of Finance CFODec 23Option Exercise2.749,60026,30434,832Dec 26 04:06 PM
Hineline Lawrence J.SVP of Finance CFODec 23Sale25.5015,032383,31619,800Dec 26 04:06 PM